Climb Bio, Inc.
For the period ended Sep 30, 2026. Filed Nov 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 5, 2026
CLYM$11.74+6.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity (Deficit)
(In thousands, except share amounts)
| Accumulated | ||||||
|---|---|---|---|---|---|---|
| Additional · Other · Total | ||||||
| Common Stock · Paid-in · Comprehensive · Accumulated · Stockholders’ | ||||||
| Shares | Amount | Capital | Income (Loss) | Deficit | Equity (Deficit) | |
| Balances at December 31, 2025 | 47,766,338 | $5 | $449,762 | $435 | $(289,727) | $160,475 |
| Vesting of restricted stock units | 563 | — | — | — | — | — |
| Issuance of common stock upon exercise of stock options | 1,642 | — | 5 | — | — | 5 |
| Stock-based compensation expense | — | — | 1,605 | — | — | 1,605 |
| Unrealized gain (loss) on marketable securities | — | — | — | (278) | — | (278) |
| Net loss | — | — | — | — | (13,722) | (13,722) |
| Balances at March 31, 2026 | 47,768,543 | $5 | $451,372 | $157 | $(303,449) | $148,085 |
| Vesting of restricted stock units | 70,275 | — | — | — | — | — |
| Issuance of common stock upon exercise of stock options | 96,078 | — | 255 | — | — | 255 |
| Issuance of common stock and pre-funded warrants in private placement, net of issuance costs | 9,481,000 | 1 | 103,368 | — | — | 103,369 |
| Issuance of common stock under equity incentive plans related to ESPP | 20,359 | — | 79 | — | — | 79 |
| Stock-based compensation expense | — | — | 1,481 | — | — | 1,481 |
| Unrealized gain (loss) on marketable securities | — | — | — | (224) | — | (224) |
| Net loss | — | — | — | — | (13,498) | (13,498) |
| Balances at June 30, 2026 | 57,436,255 | $6 | $556,555 | $(67) | $(316,947) | $239,547 |
| Issuance of common stock upon exercise of stock options | 291,923 | — | 1,504 | — | — | 1,504 |
| Stock-based compensation expense | — | — | 2,036 | — | — | 2,036 |
| Unrealized gain (loss) on marketable securities | — | — | — | (461) | — | (461) |
| Net loss | — | — | — | — | (14,573) | (14,573) |
| Balances at September 30, 2026 | 57,728,178 | $6 | $560,095 | $(528) | $(331,520) | $228,053 |
| Accumulated | ||||||
|---|---|---|---|---|---|---|
| Additional · Other · Total | ||||||
| Common Stock · Paid-in · Comprehensive · Accumulated · Stockholders’ | ||||||
| Shares | Amount | Capital | Income (Loss) | Deficit | Equity (Deficit) | |
| Balances at December 31, 2024 | 67,255,434 | $7 | $441,727 | $23 | $(229,876) | $211,881 |
| Vesting of restricted stock units | 320,333 | — | — | — | — | — |
| Stock-based compensation expense | — | — | 2,022 | — | — | 2,022 |
| Unrealized gain (loss) on marketable securities | — | — | — | 263 | — | 263 |
| Net loss | — | — | — | — | (20,781) | (20,781) |
| Balances at March 31, 2025 | 67,575,767 | $7 | $443,749 | $286 | $(250,657) | $193,385 |
| Vesting of restricted stock units | 188,333 | — | — | — | — | — |
| Stock-based compensation expense | — | — | 1,013 | — | — | 1,013 |
| Unrealized gain (loss) on marketable securities | — | — | — | 32 | — | 32 |
| Net loss | — | — | — | — | (8,666) | (8,666) |
| Balances at June 30, 2025 | 67,764,100 | $7 | $444,762 | $318 | $(259,323) | $185,764 |
| Vesting of restricted stock units | 420,335 | — | — | — | — | — |
| Stock-based compensation expense | — | — | 3,976 | — | — | 3,976 |
| Unrealized gain (loss) on marketable securities | — | — | — | 151 | — | 151 |
| Net loss | — | — | — | — | (12,888) | (12,888) |
| Balances at September 30, 2025 | 68,184,435 | $7 | $448,738 | $469 | $(272,211) | $177,003 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.